---
schema_version: "secwatch.filing_event.v1"
accession: "0001701478-25-000041"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:32:45.418448+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety

## Summary
- Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.
- Cash and equivalents $1.0M as of June 30, 2025; entered $20M equity line with Alumni Capital LP.
- ATR-12 Phase 1b in Netherton syndrome: 50% enrolled, promising safety in first 5 patients.
- ATR-04 Phase 1/2 for EGFRi rash: design presented at ASCO; first patient dosing expected Q3 2025.
- Anticipated topline data for ATR-12 in Q1 2026.

## SEC filing metadata
- accession: 0001701478-25-000041
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/0001701478-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/aztr-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701478-25-000041
- JSON: https://secwatch.observer/filing/0001701478-25-000041.json
- Plain text: https://secwatch.observer/filing/0001701478-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.